Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.9K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.1K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Adult Stem Cells01:33

Adult Stem Cells

33.9K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.9K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.6K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.6K
Embryonic Stem Cells00:57

Embryonic Stem Cells

5.1K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT.

Bone marrow transplantation·2026
Same author

European expert recommendations for comprehensive pre-treatment, treatment-phase and post-treatment care of patients with metachromatic leukodystrophy treated with autologous haematopoietic stem and progenitor cell gene therapy.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026
Same author

Descriptive Epidemiology and Prognosis of Pediatric Acute Leukemia in the Afro-Descendant Population of the French West Indies and French Guiana.

Cancer medicine·2026
Same author

Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial.

American journal of hematology·2026
Same author

Influence of Personalized Advice on Cardiovascular Management in Childhood Cancer Survivors.

Journal of adolescent and young adult oncology·2026
Same author

Evaluation of oral health and oral health-related quality of life among childhood leukemia survivors: a pilot study in the LEA cohort.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026

Related Experiment Video

Updated: Feb 10, 2026

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.0K

Hematopoietic stem cell transplantation in SCD.

Jean-Hugues Dalle1

  • 1Service d'hémato-immunologie pédiatrique, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75935 Paris cedex 19, France. jean-hugues.dalle@rdb.aphp.fr

Comptes Rendus Biologies
|May 7, 2013
PubMed
Summary

Hematopoietic stem cell transplantation (HSCT) offers a cure for severe sickle cell disease (SCD), with over 90% of patients experiencing complete recovery and improved health post-procedure. Research is exploring reduced-intensity conditioning and alternative stem cell sources to minimize side effects.

More Related Videos

Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 24, 2007

24.2K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 24, 2007

14.0K

Related Experiment Videos

Last Updated: Feb 10, 2026

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.0K
Isolation and Transplantation of Hematopoietic Stem Cells HSCs
20:38

Isolation and Transplantation of Hematopoietic Stem Cells HSCs

Published on: February 24, 2007

24.2K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 24, 2007

14.0K

Area of Science:

  • Hematology
  • Transplantation Medicine
  • Genetics

Background:

  • Severe sickle cell disease (SCD) currently has limited curative treatment options.
  • Hematopoietic stem cell transplantation (HSCT) is the only established curative therapy for severe SCD.
  • Significant advancements have been made in HSCT for SCD, particularly in France.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of HSCT in patients with severe SCD.
  • To highlight the high success rates of HSCT in SCD compared to other diseases.
  • To discuss the need for less toxic conditioning regimens and alternative stem cell sources for HSCT in SCD.

Main Methods:

  • Review of historical data and outcomes for hundreds of SCD patients undergoing genidentical HSCT.
  • Analysis of survival rates and cure rates post-HSCT since the year 2000.
  • Assessment of long-term side effects associated with myeloablative conditioning regimens.

Main Results:

  • HSCT for SCD demonstrates exceptionally high success rates, with over 95% survival and 90% cure rates.
  • The best outcomes among HSCT-treated malignant and non-malignant diseases are observed in SCD patients.
  • Myeloablative conditioning, while effective for engraftment, is associated with significant long-term side effects like hypofertility.

Conclusions:

  • HSCT is a highly effective curative treatment for severe SCD, offering excellent long-term health outcomes.
  • The success of HSCT in SCD warrants consideration for expanding indications and exploring less intensive conditioning protocols.
  • Future directions include investigating alternative stem cell sources (mismatched donors, cord blood) to improve safety and accessibility.